2. Étape, Préparation de la matrice de séquençage (amplification clonale)

A. Rogel, M. Colonna, Z. Uhry, B. Lacour, C. Schwartz et al., Incidence des cancers de la thyroïde à partir des données des registres du cancer : description sur la période, 1982.

V. Jooste, Unbiased estimates of long-term net survival of solid cancers in France, International Journal of Cancer, vol.49, issue.10, pp.2370-2377, 2013.
DOI : 10.1002/ijc.27857

M. Volante, Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach, The American Journal of Surgical Pathology, vol.31, issue.8, pp.1256-1264, 2007.
DOI : 10.1097/PAS.0b013e3180309e6a

S. I. Sherman and . Thyroid, Thyroid carcinoma, The Lancet, vol.361, issue.9356, pp.501-511, 2003.
DOI : 10.1016/S0140-6736(03)12488-9

R. C. Smallridge, American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer, Thyroid, vol.22, issue.11, pp.1104-1139, 2012.
DOI : 10.1089/thy.2012.0302

L. Davies and H. G. Welch, Increasing Incidence of Thyroid Cancer in the United States, 1973-2002, JAMA, vol.295, issue.18, pp.2164-2167, 1973.
DOI : 10.1001/jama.295.18.2164

A. Taccaliti, F. Silvetti, G. Palmonella, and M. Boscaro, Anaplastic Thyroid Carcinoma, Frontiers in Endocrinology, vol.3, p.84, 2012.
DOI : 10.3389/fendo.2012.00084

V. Zivaljevic, Risk Factors for Anaplastic Thyroid Cancer, International Journal of Endocrinology, vol.114, issue.1, p.815070, 2014.
DOI : 10.1067/msy.2001.118266

E. Kebebew, F. S. Greenspan, O. H. Clark, K. A. Woeber, and A. Mcmillan, Anaplastic thyroid carcinoma, Cancer, vol.70, issue.Suppl 2, pp.1330-1335, 2005.
DOI : 10.1002/cncr.20936

S. A. Hundahl, Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996, Cancer, vol.7, issue.1, pp.202-217, 2000.
DOI : 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A

S. Agrawal, Histologic trends in thyroid cancer 1969???1993: A clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid, Journal of Surgical Oncology, vol.65, issue.4, pp.251-255, 1996.
DOI : 10.1002/(SICI)1096-9098(199612)63:4<251::AID-JSO7>3.0.CO;2-B

P. Lampertico, Anaplastic (sarcomatoid) carcinoma of the thyroid gland, Semin. Diagn. Pathol, vol.10, pp.159-168, 1993.

P. Trimboli, Trend in Thyroid Carcinoma Size, Age at Diagnosis, and Histology in a Retrospective Study of 500 Cases Diagnosed Over 20 Years, Thyroid, vol.16, issue.11, pp.1151-1155, 2006.
DOI : 10.1089/thy.2006.16.1151

C. Passler, Anaplastic (undifferentiated) thyroid carcinoma (ATC), Langenbeck's Archives of Surgery, vol.384, issue.3, pp.284-293, 1999.
DOI : 10.1007/s004230050205

B. Dijkstra, Changing patterns of thyroid carcinoma. Ir, J. Med. Sci, vol.176, pp.87-90, 2007.

F. Bakiri, F. K. Djemli, L. A. Mokrane, and F. K. Djidel, The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma, Cancer, vol.9, issue.6, pp.1146-1153, 1998.
DOI : 10.1002/(SICI)1097-0142(19980315)82:6<1146::AID-CNCR20>3.0.CO;2-5

N. Besic, M. Hocevar, and J. Zgajnar, Lower Incidence of Anaplastic Carcinoma After Higher Iodination of Salt in Slovenia, Thyroid, vol.20, issue.6, pp.623-626, 2010.
DOI : 10.1089/thy.2009.0404

G. Wallin, Co-existent anaplastic and well differentiated thyroid carcinomas: a nuclear DNA study, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol, vol.15, pp.43-48, 1989.

B. Mciver, Anaplastic thyroid carcinoma: A 50-year experience at a single institution, Surgery, vol.130, issue.6, pp.1028-1034, 2001.
DOI : 10.1067/msy.2001.118266

J. R. Spires, M. R. Schwartz, and R. H. Miller, Anaplastic Thyroid Carcinoma: Association With Differentiated Thyroid Cancer, Archives of Otolaryngology - Head and Neck Surgery, vol.114, issue.1, pp.40-44, 1988.
DOI : 10.1001/archotol.1988.01860130044012

S. A. Hundahl, I. D. Fleming, A. M. Fremgen, and H. R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U, S, vol.83, pp.2638-2648, 1985.

D. Giuffrida and H. Gharib, Cardiac metastasis from primary anaplastic thyroid carcinoma: report of three cases and a review of the literature, Endocrine Related Cancer, vol.8, issue.1, pp.71-73, 2001.
DOI : 10.1677/erc.0.0080071

G. Belleannée, H. Trouette, and A. De-mascarel, Enseignement Post-Universitaire -Prise en charge pratique et diagnostique des prélèvements thyroïdiens : cytoponctions, extemporanés

Y. S. Venkatesh, Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases, Cancer, vol.7, issue.2, pp.321-330, 1990.
DOI : 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A

M. L. Carcangiu, T. Steeper, G. Zampi, and J. Rosai, Anaplastic Thyroid Carcinoma: A Study of 70 Cases, American Journal of Clinical Pathology, vol.83, issue.2, pp.135-158, 1985.
DOI : 10.1093/ajcp/83.2.135

M. Ragazzi, Update on Anaplastic Thyroid Carcinoma: Morphological, Molecular, and Genetic Features of the Most Aggressive Thyroid Cancer, International Journal of Endocrinology, vol.70, issue.1, p.790834, 2014.
DOI : 10.1089/thy.2011.0258

J. C. Canos, A. Serrano, and X. Matias-guiu, Paucicellular Variant of Anaplastic Thyroid Carcinoma: Report of Two Cases, Endocrine Pathology, vol.12, issue.2, pp.157-161, 2001.
DOI : 10.1385/EP:12:2:157

M. J. Gaffey, E. E. Lack, M. L. Christ, and L. M. Weiss, Anaplastic Thyroid Carcinoma with Osteoclast-like Giant Cells, The American Journal of Surgical Pathology, vol.15, issue.2, pp.160-168, 1991.
DOI : 10.1097/00000478-199102000-00009

G. Feng, W. B. Laskin, P. M. Chou, and X. Lin, Anaplastic thyroid carcinoma with rhabdoid features, Diagnostic Cytopathology, vol.7, issue.5, pp.416-420, 2015.
DOI : 10.1002/dc.23254

M. Olthof, A. C. Persoon, J. T. Plukker, J. E. Van-der-wal, and T. P. Links, Anaplastic Thyroid Carcinoma with Rhabdomyoblastic Differentiation: A Case Report with a Good Clinical Outcome, Endocrine Pathology, vol.202, issue.1, pp.62-65, 2008.
DOI : 10.1007/s12022-008-9017-3

M. L. Lai, Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma, Arch. Pathol. Lab. Med, vol.129, pp.55-57, 2005.

H. Dominguez-malagon, G. Flores-flores, and J. J. Vilchis, Lymphoepithelioma-like anaplastic thyroid carcinoma: Report of a case not related to Epstein-Barr virus, Annals of Diagnostic Pathology, vol.5, issue.1, pp.21-24, 2001.
DOI : 10.1053/adpa.2001.21480

A. Tobler, R. Maurer, and C. Hedinger, Undifferentiated thyroid tumors of diffuse small cell type, Virchows Archiv A Pathological Anatomy and Histopathology, vol.10, issue.2, pp.117-126, 1984.
DOI : 10.1007/BF00704057

R. C. Smallridge and J. A. Copland, Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies, Clinical Oncology, vol.22, issue.6, pp.486-497, 2010.
DOI : 10.1016/j.clon.2010.03.013

M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer, Nature Reviews Cancer, vol.57, issue.3, pp.184-199, 2013.
DOI : 10.1038/nrc3431

T. Kondo, S. Ezzat, and S. L. Asa, Pathogenetic mechanisms in thyroid follicular-cell neoplasia, Nature Reviews Cancer, vol.88, issue.4, pp.292-306, 2006.
DOI : 10.1038/nrc1836

M. Xing, Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications, Otolaryngologic Clinics of North America, vol.41, issue.6, pp.1135-1146, 2008.
DOI : 10.1016/j.otc.2008.07.001

A. K. Murugan and M. Xing, Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene, Cancer Research, vol.71, issue.13, pp.4403-4411, 2011.
DOI : 10.1158/0008-5472.CAN-10-4041

D. Liaw, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, Nature Genetics, vol.57, issue.1, pp.64-67, 1997.
DOI : 10.1001/jama.276.19.1575

V. Vasko, Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer, Journal of Medical Genetics, vol.41, issue.3, pp.161-170, 2004.
DOI : 10.1136/jmg.2003.015339

M. D. Ringel, Overexpression and overactivation of Akt in thyroid carcinoma, Cancer Res, vol.61, pp.6105-6111, 2001.

J. C. Ricarte-filho, Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1, Cancer Research, vol.69, issue.11, pp.4885-4893, 2009.
DOI : 10.1158/0008-5472.CAN-09-0727

P. H. Abbosh and K. P. Nephew, Multiple Signaling Pathways Converge on ??-Catenin in Thyroid Cancer, Thyroid, vol.15, issue.6, pp.551-561, 2005.
DOI : 10.1089/thy.2005.15.551

N. Burrows, Expression of hypoxia-inducible factor 1?? in thyroid carcinomas, Endocrine Related Cancer, vol.17, issue.1, pp.61-72, 2010.
DOI : 10.1677/ERC-08-0251

N. Burrows, GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1?? (HIF-1??) Pathways, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.12, pp.1934-1943, 2011.
DOI : 10.1210/jc.2011-1426

C. J. Guigon, L. Zhao, M. C. Willingham, and S. Cheng, PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer, Oncogene, vol.27, issue.4, pp.509-517, 2009.
DOI : 10.1093/carcin/bgg111

M. Karin, NF-??B as a Critical Link Between Inflammation and Cancer, Cold Spring Harbor Perspectives in Biology, vol.1, issue.5, p.141, 2009.
DOI : 10.1101/cshperspect.a000141

F. Pacifico and A. Leonardi, Role of NF-??B in thyroid cancer, Molecular and Cellular Endocrinology, vol.321, issue.1, pp.29-35, 2010.
DOI : 10.1016/j.mce.2009.10.010

X. Li, A. B. Abdel-mageed, D. Mondal, and E. Kandil, The Nuclear Factor Kappa-B Signaling Pathway as a Therapeutic Target Against Thyroid Cancers, Thyroid, vol.23, issue.2, pp.209-218, 2013.
DOI : 10.1089/thy.2012.0237

I. Palona, Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor ??B Activation, Endocrinology, vol.147, issue.12, pp.5699-5707, 2006.
DOI : 10.1210/en.2006-0400

D. Liu and M. Xing, Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-??B Pathways, Thyroid, vol.18, issue.8, pp.853-864, 2008.
DOI : 10.1089/thy.2007.0357

H. Clevers and R. Nusse, Wnt/??-Catenin Signaling and Disease, Cell, vol.149, issue.6, pp.1192-1205, 2012.
DOI : 10.1016/j.cell.2012.05.012

G. Garcia-rostan, Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma, Cancer Res, vol.59, pp.1811-1815, 1999.

G. Garcia-rostan, ??-Catenin Dysregulation in Thyroid Neoplasms, The American Journal of Pathology, vol.158, issue.3, pp.987-996, 2001.
DOI : 10.1016/S0002-9440(10)64045-X

S. M. Wiseman, O. L. Griffith, A. Gown, B. Walker, and S. J. Jones, Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma, The American Journal of Surgery, vol.201, issue.5, pp.580-586, 2011.
DOI : 10.1016/j.amjsurg.2011.01.010

A. Sastre-perona and P. Santisteban, Role of the Wnt Pathway in Thyroid Cancer, Frontiers in Endocrinology, vol.3, p.31, 2012.
DOI : 10.3389/fendo.2012.00031

C. Lu, X. Zhu, M. C. Willingham, and S. Cheng, Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma, Oncogene, vol.63, issue.16, pp.2007-2016, 2012.
DOI : 10.1038/sj.onc.1210680

M. D. Castellone, The ??-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell Proliferation, Cancer Research, vol.69, issue.5, pp.1867-1876, 2009.
DOI : 10.1158/0008-5472.CAN-08-1982

S. Lamouille, J. Xu, and R. Derynck, Molecular mechanisms of epithelial???mesenchymal transition, Nature Reviews Molecular Cell Biology, vol.22, issue.3, pp.178-196, 2014.
DOI : 10.1038/nrm3758

M. Xing, Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis, Cancer Research, vol.64, issue.5, pp.1664-1668, 2004.
DOI : 10.1158/0008-5472.CAN-03-3242

S. Scarpino, Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1(HIF-1) in tumour cells in papillary carcinoma of the thyroid, The Journal of Pathology, vol.202, issue.3, pp.352-358, 2004.
DOI : 10.1002/path.1522

J. Lyons, Two G protein oncogenes in human endocrine tumors, Science, vol.249, issue.4969, pp.655-659, 1990.
DOI : 10.1126/science.2116665

J. Parma, Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas, Nature, vol.365, issue.6447, pp.649-651, 1993.
DOI : 10.1038/365649a0

R. F. Rodrigues, L. Roque, J. Rosa-santos, O. Cid, and J. Soares, Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas, British Journal of Cancer, vol.90, issue.2, pp.492-496, 2004.
DOI : 10.1038/sj.bjc.6601530

V. B. Wreesmann, Genome-Wide Appraisal of Thyroid Cancer Progression, The American Journal of Pathology, vol.161, issue.5, pp.1549-1556, 2002.
DOI : 10.1016/S0002-9440(10)64433-1

S. Hemmer, V. M. Wasenius, S. Knuutila, K. Franssila, and H. Joensuu, DNA Copy Number Changes in Thyroid Carcinoma, The American Journal of Pathology, vol.154, issue.5, pp.1539-1547, 1999.
DOI : 10.1016/S0002-9440(10)65407-7

Y. Kitamura, K. Shimizu, S. Tanaka, K. Ito, and M. Emi, Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, Genes. Chromosomes Cancer, vol.17, issue.27, pp.19-22, 2000.

Z. Liu, Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.3106-3116, 2008.
DOI : 10.1210/jc.2008-0273

E. Miyagi, Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells, Molecular Carcinogenesis, vol.84, issue.2, pp.98-107, 2004.
DOI : 10.1002/mc.20042

N. L. Eberhardt, S. K. Grebe, B. Mciver, and H. Reddi, The role of the PAX8/PPAR?? fusion oncogene in the pathogenesis of follicular thyroid cancer, Molecular and Cellular Endocrinology, vol.321, issue.1, pp.50-56, 2010.
DOI : 10.1016/j.mce.2009.10.013

U. Schagdarsurengin, O. Gimm, H. Dralle, C. Hoang-vu, and R. Dammann, CpG Island Methylation of Tumor-Related Promoters Occurs Preferentially in Undifferentiated Carcinoma, Thyroid, vol.16, issue.7, pp.633-642, 2006.
DOI : 10.1089/thy.2006.16.633

R. Visone, Specific microRNAs are downregulated in human thyroid anaplastic carcinomas, Oncogene, vol.91, issue.54, pp.7590-7595, 2007.
DOI : 10.1038/sj.onc.1210564

M. T. Berlingieri, G. M. Pierantoni, V. Giancotti, M. Santoro, and A. Fusco, Thyroid cell transformation requires the expression of the HMGA1 proteins, Oncogene, vol.21, issue.19, pp.2971-2980, 2002.
DOI : 10.1038/sj.onc.1205368

S. Mitomo, Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines, Cancer Science, vol.2, issue.2, pp.280-286, 2008.
DOI : 10.1038/ncb985

S. Takakura, Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells, Cancer Science, vol.88, issue.6, pp.1147-1154, 2008.
DOI : 10.1111/j.1349-7006.2008.00800.x

P. Hou, M. Ji, and M. Xing, gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors, Cancer, vol.90, issue.9, pp.2440-2447, 2008.
DOI : 10.1002/cncr.23869

M. Shiota, Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry, Blood, vol.84, pp.3648-3652, 1994.

S. W. Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma, Science, vol.263, issue.5151, pp.316-317, 1995.
DOI : 10.1126/science.8122112

P. Minoo and H. Wang, ALK-immunoreactive neoplasms, Int. J. Clin. Exp. Pathol, vol.5, pp.397-410, 2012.

K. Hamatani, RET/PTC Rearrangements Preferentially Occurred in Papillary Thyroid Cancer among Atomic Bomb Survivors Exposed to High Radiation Dose, Cancer Research, vol.68, issue.17, pp.7176-7182, 2008.
DOI : 10.1158/0008-5472.CAN-08-0293

Y. Godbert, Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase???Rearranged Anaplastic Thyroid Carcinoma, Journal of Clinical Oncology, vol.33, issue.20, 2014.
DOI : 10.1200/JCO.2013.49.6596

G. Pérot, Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas, PLoS ONE, vol.8, issue.1, p.87170, 2014.
DOI : 10.1371/journal.pone.0087170.s003

T. Iwahara, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system, Oncogene, vol.14, issue.4, pp.439-449, 1997.
DOI : 10.1038/sj.onc.1200849

R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami, The anaplastic lymphoma kinase in the pathogenesis of cancer, Nature Reviews Cancer, vol.159, issue.1, pp.11-23, 2008.
DOI : 10.1002/ijc.21490

E. L. Kwak, Anaplastic Lymphoma Kinase Inhibition in Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.363, issue.18, pp.1693-1703, 2010.
DOI : 10.1056/NEJMoa1006448

C. M. Coffin, ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor, Modern Pathology, vol.14, issue.6, pp.569-576, 2001.
DOI : 10.1038/modpathol.3880352

P. I. Haigh, Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival, Cancer, vol.83, issue.12, pp.2335-2342, 2001.
DOI : 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1

C. Y. Lo, K. Y. Lam, and K. Wan, Anaplastic carcinoma of the thyroid, The American Journal of Surgery, vol.177, issue.4, pp.337-339, 1999.
DOI : 10.1016/S0002-9610(99)00052-5

I. Sugitani, N. Kasai, Y. Fujimoto, and A. Yanagisawa, Prognostic Factors and Therapeutic Strategy for Anaplastic Carcinoma of the Thyroid, World Journal of Surgery, vol.25, issue.5, pp.617-622, 2001.
DOI : 10.1007/s002680020166

P. E. Voutilainen, M. Multanen, R. K. Haapiainen, A. K. Leppäniemi, and A. H. Sivula, Anaplastic Thyroid Carcinoma Survival, World Journal of Surgery, vol.23, issue.9, pp.975-978, 1999.
DOI : 10.1007/s002689900610

B. Roche, Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature, Annales d'Endocrinologie, vol.71, issue.1, pp.38-45, 2010.
DOI : 10.1016/j.ando.2009.10.013

J. Chen, J. D. Tward, D. C. Shrieve, and Y. J. Hitchcock, Surgery and Radiotherapy Improves Survival in Patients With Anaplastic Thyroid Carcinoma, American Journal of Clinical Oncology, vol.31, issue.5, pp.460-464, 2008.
DOI : 10.1097/COC.0b013e31816a61f3

F. D. Gilliland, W. C. Hunt, D. M. Morris, and C. R. Key, Prognostic factors for thyroid carcinoma, Cancer, vol.64, issue.3, pp.564-573, 1997.
DOI : 10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0

R. K. Tan, Anaplastic carcinoma of the thyroid: A 24-year experience, Head & Neck, vol.24, issue.1, pp.41-47, 1995.
DOI : 10.1002/hed.2880170109

R. C. Smallridge, Approach to the Patient with Anaplastic Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.8, pp.2566-2572, 2012.
DOI : 10.1210/jc.2012-1314

G. Nagaiah, A. Hossain, C. J. Mooney, J. Parmentier, and S. C. Remick, Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment, Journal of Oncology, vol.167, issue.6, p.542358, 2011.
DOI : 10.1089/thy.2008.0281

J. Tennvall, Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery, British Journal of Cancer, vol.20, issue.12, pp.1848-1853, 2002.
DOI : 10.1016/S0304-3835(97)04742-3

P. Dandekar, Hyperfractionated Accelerated Radiotherapy (HART) for Anaplastic Thyroid Carcinoma: Toxicity and Survival Analysis, International Journal of Radiation Oncology*Biology*Physics, vol.74, issue.2, pp.518-521, 2009.
DOI : 10.1016/j.ijrobp.2008.08.016

C. S. Wong, J. Van-dyk, and W. J. Simpson, Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma, Radiotherapy and Oncology, vol.20, issue.1, pp.3-9, 1991.
DOI : 10.1016/0167-8140(91)90105-P

A. Bhatia, Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy, Head & Neck, vol.62, pp.829-836, 2010.
DOI : 10.1002/hed.21257

C. M. Nutting, Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland, Radiotherapy and Oncology, vol.60, issue.2, pp.173-180, 2001.
DOI : 10.1016/S0167-8140(01)00382-6

C. Regalbuto, Update on thyroid cancer treatment, Future Oncology, vol.8, issue.10, pp.1331-1348, 2012.
DOI : 10.2217/fon.12.123

V. Gupta-abramson, Phase II Trial of Sorafenib in Advanced Thyroid Cancer, Journal of Clinical Oncology, vol.26, issue.29, pp.4714-4719, 2008.
DOI : 10.1200/JCO.2008.16.3279

S. Kim, Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice, Molecular Cancer Therapeutics, vol.6, issue.6, pp.1785-1792, 2007.
DOI : 10.1158/1535-7163.MCT-06-0595

S. Faivre, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, The Lancet Oncology, vol.10, issue.8, pp.794-800, 2009.
DOI : 10.1016/S1470-2045(09)70171-8

E. Grande, J. Capdevila, J. J. Díez, F. Longo, and A. Carrato, A significant response to sunitinib in a patient with anaplastic thyroid carcinoma, J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci, vol.18, pp.623-625, 2013.

J. D. Schoenfeld, O. O. Odejide, L. J. Wirth, and A. W. Chan, Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report, Anticancer Res, vol.32, pp.1743-1746, 2012.

K. C. Bible, A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.9, pp.3179-3184, 2012.
DOI : 10.1210/jc.2012-1520

E. E. Cohen, Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study, Journal of Clinical Oncology, vol.26, issue.29, pp.4708-4713, 2008.
DOI : 10.1200/JCO.2007.15.9566

M. H. Rosove, P. F. Peddi, and J. A. Glaspy, BRAF V600E Inhibition in Anaplastic Thyroid Cancer, New England Journal of Medicine, vol.368, issue.7, pp.684-685, 2013.
DOI : 10.1056/NEJMc1215697

H. T. Ha, A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer, Thyroid, vol.20, issue.9, pp.975-980, 2010.
DOI : 10.1089/thy.2010.0057

K. Masago, M. Miura, Y. Toyama, Y. Togashi, and M. Mishima, Good Clinical Response to Erlotinib in a Patient With Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21, Journal of Clinical Oncology, vol.29, issue.16, pp.465-467, 2011.
DOI : 10.1200/JCO.2010.34.0216

T. Hogan, Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib, Journal of Oncology Pharmacy Practice, vol.31, issue.8, pp.111-117, 2009.
DOI : 10.1177/1078155208101212

N. A. Pennell, A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer, Thyroid, vol.18, issue.3, pp.317-323, 2008.
DOI : 10.1089/thy.2007.0120

C. J. Mooney, A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome, Thyroid, vol.19, issue.3, pp.233-240, 2009.
DOI : 10.1089/thy.2008.0321

K. Hamatani, ) Gene in Adult-Onset Papillary Thyroid Cancer Amongst Atomic Bomb Survivors, Thyroid, vol.22, issue.11, pp.1153-1159, 2012.
DOI : 10.1089/thy.2011.0511

M. J. Demeure, Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4???ALK Translocation as a Therapeutic Target, World Journal of Surgery, vol.40, issue.14, pp.1296-1305, 2014.
DOI : 10.1007/s00268-014-2485-3

L. M. Kelly, Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer, Proceedings of the National Academy of Sciences, vol.111, issue.11, pp.4233-4238, 2014.
DOI : 10.1073/pnas.1321937111

C. D. Mcfarland, K. S. Korolev, G. V. Kryukov, S. R. Sunyaev, and L. A. Mirny, Impact of deleterious passenger mutations on cancer progression, Proceedings of the National Academy of Sciences, vol.110, issue.8, pp.2910-2915, 2013.
DOI : 10.1073/pnas.1213968110

M. Ilie and P. Hofman, Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?, Current Medicinal Chemistry, vol.19, issue.16, pp.2638-2651, 2012.
DOI : 10.2174/092986712800493002

K. Wu, R. S. Huang, L. House, and W. C. Cho, Next-generation sequencing for lung cancer, Future Oncology, vol.9, issue.9, pp.1323-1336, 2013.
DOI : 10.2217/fon.13.102

J. Kononen, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nature Medicine, vol.54, issue.7, pp.844-847, 1998.
DOI : 10.1023/A:1005769925670

A. Nocito, J. Kononen, O. P. Kallioniemi, and G. Sauter, Tissue microarrays (TMAs) for high-throughput molecular pathology research, International Journal of Cancer, vol.65, issue.1, pp.1-5, 2001.
DOI : 10.1002/ijc.1385

E. S. Yi, Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH, Journal of Thoracic Oncology, vol.6, issue.3, pp.459-465, 2011.
DOI : 10.1097/JTO.0b013e318209edb9

Y. H. Kim, S. Choi, S. O. Yoon, and S. W. Hong, A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma, Human Pathology, vol.45, issue.7, pp.1483-1488, 2014.
DOI : 10.1016/j.humpath.2014.02.025

I. Soubeyran, Tissue Microarray Cytometry Reveals Positive Impact of Homeodomain Interacting Protein Kinase 2 in Colon Cancer Survival Irrespective of p53 Function, The American Journal of Pathology, vol.178, issue.5, pp.1986-1998, 2011.
DOI : 10.1016/j.ajpath.2011.01.021

D. R. Spigel, Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.13, issue.6, pp.500-504, 2012.
DOI : 10.1016/j.cllc.2012.05.009

S. Beg, PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma, British Journal of Cancer, vol.18, issue.12, pp.1938-1943, 2015.
DOI : 10.1002/cncr.11175

C. Audebert, R. Blervaque, and G. Even, Survol de la technologie de séquençage PGM Ion Torrent

A. Chou, A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma, The American Journal of Surgical Pathology, vol.39, issue.5, pp.652-659, 2015.
DOI : 10.1097/PAS.0000000000000368

M. Xing, Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications, Endocrine Reviews, vol.28, issue.7, pp.742-762, 2007.
DOI : 10.1210/er.2007-0007

M. Xing, BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.12, pp.6373-6379, 2005.
DOI : 10.1210/jc.2005-0987

D. Chakravarty, Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation, Journal of Clinical Investigation, vol.121, issue.12, pp.4700-4711, 2011.
DOI : 10.1172/JCI46382DS1

R. Charles, G. Iezza, E. Amendola, D. Dankort, and M. Mcmahon, Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse, Cancer Research, vol.71, issue.11, pp.3863-3871, 2011.
DOI : 10.1158/0008-5472.CAN-10-4463

J. A. Knauf, Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation, Cancer Research, vol.65, issue.10, pp.4238-4245, 2005.
DOI : 10.1158/0008-5472.CAN-05-0047

M. N. Nikiforova, Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.11, pp.5399-5404, 2003.
DOI : 10.1210/jc.2003-030838

N. Mitsutake, Conditional BRAFV600E Expression Induces DNA Synthesis, Apoptosis, Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells, Cancer Research, vol.65, issue.6, pp.2465-2473, 2005.
DOI : 10.1158/0008-5472.CAN-04-3314

S. Begum, BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment, Modern Pathology, vol.4, issue.11, pp.1359-1363, 2004.
DOI : 10.1038/modpathol.3800198

D. Handkiewicz-junak, A. Czarniecka, and B. Jarzab, Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions, Molecular and Cellular Endocrinology, vol.322, issue.1-2, pp.8-28, 2010.
DOI : 10.1016/j.mce.2010.01.007

H. G. Suárez, Detection of activated ras oncogenes in human thyroid carcinomas, Oncogene, vol.2, pp.403-406, 1988.

N. R. Lemoine, Activated ras oncogenes in human thyroid cancers, Cancer Res, vol.48, pp.4459-4463, 1988.

Y. E. Nikiforov, Thyroid carcinoma: molecular pathways and therapeutic targets, Modern Pathology, vol.98, pp.37-43, 2008.
DOI : 10.1038/nature04304

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673022

L. A. Cass and J. L. Meinkoth, Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation, Oncogene, vol.19, issue.7, pp.924-932, 2000.
DOI : 10.1038/sj.onc.1203393

I. Bongarzone, High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma, Oncogene, vol.4, pp.1457-1462, 1989.

M. Saji and M. D. Ringel, The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors, Molecular and Cellular Endocrinology, vol.321, issue.1, pp.20-28, 2010.
DOI : 10.1016/j.mce.2009.10.016

L. Santarpia, A. K. El-naggar, G. J. Cote, J. N. Myers, and S. I. Sherman, Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.1, pp.278-284, 2008.
DOI : 10.1210/jc.2007-1076

J. W. Kunstman, Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing, Human Molecular Genetics, vol.24, issue.8, pp.2318-2329, 2015.
DOI : 10.1093/hmg/ddu749

J. A. Fagin, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas., Journal of Clinical Investigation, vol.91, issue.1, pp.179-184, 1993.
DOI : 10.1172/JCI116168

R. Donghi, Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland., Journal of Clinical Investigation, vol.91, issue.4, pp.1753-1760, 1993.
DOI : 10.1172/JCI116385

D. G. Mcfadden, p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer, Proceedings of the National Academy of Sciences, vol.111, issue.16, pp.1600-1609, 2014.
DOI : 10.1073/pnas.1404357111

J. M. Pita, I. F. Figueiredo, M. M. Moura, V. Leite, and B. M. Cavaco, Mutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid Carcinomas, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.3, pp.497-507, 2014.
DOI : 10.1210/jc.2013-1512

F. Moretti, p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells, Oncogene, vol.14, issue.6, pp.729-740, 1997.
DOI : 10.1038/sj.onc.1200887

M. V. Blagosklonny, Effects of p53-Expressing Adenovirus on the Chemosensitivity and Differentiation of Anaplastic Thyroid Cancer Cells, The Journal of Clinical Endocrinology & Metabolism, vol.83, issue.7, pp.2516-2522, 1998.
DOI : 10.1210/jcem.83.7.4984

P. Hou, Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer, Clinical Cancer Research, vol.13, issue.4, pp.1161-1170, 2007.
DOI : 10.1158/1078-0432.CCR-06-1125

I. Sansal and W. Sellers, Tumor Suppressor Pathway, Journal of Clinical Oncology, vol.22, issue.14, pp.2954-2963, 2004.
DOI : 10.1200/JCO.2004.02.141

A. Arciuch and V. G. , Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors, Oncotarget, vol.2, issue.12, pp.1109-1126, 2011.
DOI : 10.18632/oncotarget.380

K. Zeki, D. Spambalg, N. Sharifi, R. Gonsky, and J. A. Fagin, Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms, J. Clin. Endocrinol. Metab, vol.79, pp.1317-1321, 1994.

M. M. Mondi, HER2 expression in thyroid tumors, Am. Surg, vol.69, pp.1100-1103, 2003.

R. Kremser, Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease, Virchows Arch. Int. J. Pathol, vol.442, pp.322-328, 2003.

J. C. Utrilla, I. Martín-lacave, M. V. San-martín, J. M. Fernández-santos, and H. Galera-davidson, Expression of c-erbB-2 oncoprotein in human thyroid tumours, Histopathology, vol.30, issue.1, pp.60-65, 1999.
DOI : 10.1038/328170a0

D. D. Elliott, Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification, Human Pathology, vol.39, issue.1, pp.15-20, 2008.
DOI : 10.1016/j.humpath.2007.05.012

H. Greulich, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2, Proceedings of the National Academy of Sciences, vol.109, issue.36, pp.14476-14481, 2012.
DOI : 10.1073/pnas.1203201109

T. Shimamura, Non-Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272, Cancer Research, vol.66, issue.13, pp.6487-6491, 2006.
DOI : 10.1158/0008-5472.CAN-06-0971

R. K. Kancha, Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib, PLoS ONE, vol.6, issue.10, p.26760, 2011.
DOI : 10.1371/journal.pone.0026760.s007

S. Uchino, Exons 12 and 15 in Sporadic Medullary Thyroid Carcinomas: Different Spectrum of Mutations in Sporadic Type from Hereditary Type, Japanese Journal of Cancer Research, vol.18, issue.11, pp.1231-1237, 1999.
DOI : 10.1111/j.1349-7006.1999.tb00701.x

E. Arighi, M. G. Borrello, and H. Sariola, RET tyrosine kinase signaling in development and cancer, Cytokine & Growth Factor Reviews, vol.16, issue.4-5, pp.441-467, 2005.
DOI : 10.1016/j.cytogfr.2005.05.010

L. M. Mulligan and B. A. Ponder, Genetic basis of endocrine disease: multiple endocrine neoplasia type 2, J. Clin. Endocrinol. Metab, vol.80, pp.1989-1995, 1995.

D. Lazzereschi, A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours, Oncogene, vol.159, issue.34, pp.5344-5354, 2005.
DOI : 10.1038/sj.onc.1202866

C. H. Heldin, K. Miyazono, P. Dijke, and . Ten, TGF-beta signalling from cell membrane to nucleus through SMAD proteins, Nature, vol.390, issue.6659, pp.465-471, 1997.
DOI : 10.1038/37284

C. Boltze, Hypermethylation of the CDKN2/p16INK4A Promotor in Thyroid Carcinogenesis, Pathology - Research and Practice, vol.199, issue.6, pp.399-404, 2003.
DOI : 10.1078/0344-0338-00436

W. S. Tung, Infrequent CDKN2 mutation in human differentiated thyroid cancers, Molecular Carcinogenesis, vol.15, issue.1, pp.5-10, 1996.
DOI : 10.1002/(SICI)1098-2744(199601)15:1<5::AID-MC2>3.3.CO;2-9

V. Calabrò, Status and expression of the p16INK4 gene in human thyroid tumors and thyroid???tumor cell lines, International Journal of Cancer, vol.67, issue.1, pp.29-34, 1996.
DOI : 10.1002/(SICI)1097-0215(19960703)67:1<29::AID-IJC7>3.3.CO;2-P

Y. Shiloh, The ATM-mediated DNA-damage response: taking shape, Trends in Biochemical Sciences, vol.31, issue.7, pp.402-410, 2006.
DOI : 10.1016/j.tibs.2006.05.004

K. K. Khanna and G. Chenevix-trench, ATM and Genome Maintenance: Defining Its Role in Breast Cancer Susceptibility, Journal of Mammary Gland Biology and Neoplasia, vol.9, issue.3, pp.247-262, 2004.
DOI : 10.1023/B:JOMG.0000048772.92326.a1

P. Soares, E. Fonseca, D. Wynford-thomas, and M. Sobrinho-simões, Sporadic ret???rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?, The Journal of Pathology, vol.185, issue.1, pp.71-78, 1998.
DOI : 10.1002/(SICI)1096-9896(199805)185:1<71::AID-PATH42>3.3.CO;2-J

G. Tallini, PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.4, pp.287-294, 1998.

M. N. Nikiforova, A. I. Wald, S. Roy, M. B. Durso, and Y. E. Nikiforov, Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.11, pp.1852-1860, 2013.
DOI : 10.1210/jc.2013-2292

E. A. Collisson, A Central Role for RAF???MEK???ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma, Cancer Discovery, vol.2, issue.8, pp.685-693, 2012.
DOI : 10.1158/2159-8290.CD-11-0347

T. Takano, Fetal cell carcinogenesis of the thyroid: A modified theory based on recent evidence [My Opinion], Endocrine Journal, vol.61, issue.4, pp.311-320, 2014.
DOI : 10.1507/endocrj.EJ13-0517

D. Castillo and M. , Test de la sonde commerciale RET ZYTOVISION sur des carcinomes papillaires de la thyroïde avec le kit ZYTOVISION